FDA Approves Ponatinib for Chronic-Phase CML
The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for ponatinib to treat adults with chronic-phase chronic myeloid leukemia...
Large Meta-Analysis Confirms Predictive Value of MRD Negativity in Myeloma
Achievement of measurable residual disease (MRD) negativity is associated with significant improvements in progression-free survival (PFS) and overall survival (OS) in patients with multiple...
Selinexor Combination Approved for Patients with Multiple Myeloma
The FDA has approved selinexor in combination with bortezomib and dexamethasone (Vd) for the treatment of adults with multiple myeloma (MM) who have received...
Azacitidine Maintenance Fails to Improve Post-Transplant Outcomes in High-Risk AML and MDS
Maintenance treatment with single-agent azacitidine at a dose of 32 mg/m2 daily for five days did not lead to improved survival in patients with...
Registry Analysis Finds Patients With Hematologic Malignancies Are Highly Vulnerable to COVID-19
In an analysis of data from the first 250 patients enrolled in the American Society of Hematology Research Collaborative (ASH RC) COVID-19 Registry for...
Discontinuing Eculizumab is Safe and Feasible in Patients With Atypical Hemolytic Uremic Syndrome
Discontinuation of anti-C5 agent eculizumab is feasible and safe in patients with atypical hemolytic uremic syndrome (aHUS), particularly in the 40% to 60% of...
Rethinking Autoimmune Neutropenia in Children
Authors of a registry analysis published in Blood Advances have identified two distinct autoimmune neutropenia entities in children who present with apparent primary autoimmune...
Devimistat Receives FDA Fast Track Designation for AML
The FDA has granted fast track designation to devimistat for the treatment of acute myeloid leukemia (AML), clearing its manufacturer, Rafael Pharmaceuticals, to begin...
NIH’s ACTIV Trial Suspends Enrollment of Critically Ill Patients With COVID-19
The National Institutes of Health (NIH) announced that it is pausing enrollment of patients with severe COVID-19 in three trials that are evaluating anticoagulants...
Remembering Mark Smith, Cancer Researchers Receive 2020 AAAS Fellow Distinction, and more
Remembering Mark Smith (1962 - 2020)
Mark P. Smith, MBChB, died suddenly on September 24, 2020, at the age of 58.Since 1995, Dr. Smith has...
Current Issue
January 2021 Annual Meeting Edition
This issue features highlights from the 2020 ASH Annual Meeting, a look at patient holiday gift customs around the world, and more.